Skip to main content
. Author manuscript; available in PMC: 2014 Mar 13.
Published in final edited form as: Circulation. 2013 Feb 7;127(10):1116–1127. doi: 10.1161/CIRCULATIONAHA.112.000855

Figure 2.

Figure 2

Deficiency of cystathionine gamma lyase (CSE) exacerbates cardiac dysfunction following TAC, whereas overexpression of CSE attenuates cardiac dysfunction. (A) Myocardial weights (mg/cm) and lung weights (mg/cm) expressed as ratio of tibia length at 12 weeks following TAC in wild-type (WT+TAC) mice, CSE deficient (CSE KO+TAC) mice, and CSE KO mice treated with SG1002 (CSE KO+TAC+SG-1002). (B) LV end-systolic diameter (LVESD in mm) and (C) LV ejection fraction (%) following TAC. (D) Myocardial weights (mg/cm) and lung weights (mg/cm) expressed as ratio of tibia length at 12 weeks of TAC in wild-type (WT+TAC) and cardiac specific CSE transgenic mice (CS-CSE Tg+TAC). (E) LVESD and (F) LV ejection fraction from 1 week to 12 weeks of TAC in WT and CS-CSE Tg mice. Results are expressed as mean ± SEM. †p<0.05, ‡p<0.01 and #p<0.001 vs. WT. *p<0.05, **p<.01, and ***p<0.001 vs. Baseline.

HHS Vulnerability Disclosure